Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
KEGG   DRUG: Lorvotuzumab mertansine
Entry
D09927                      Drug                                   
Name
Lorvotuzumab mertansine (USAN/INN)
Formula
C6504H10074N1758O2004S46
Exact mass
146342.7576
Mol weight
146433.24
Sequence
(Heavy chain)
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SFGMHWVRQA PGKGLEWVAY ISSGSFTIYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARMR KGYAMDYWGQ GTLVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
DVVMTQSPLS LPVTLGQPAS ISCRSSQIII HSDGNTYLEW FQQRPGQSPR RLIYKVSNRF
SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP HTFGQGTKVE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H96, H145-H201, H262-H322, H368-H426, H227-H'227, H230-H'230, L23-L93, L139-L199, H221-L219)
  Type
Peptide
Efficacy
Antineoplastic
  Type
Antibody-drug conjugate
Comment
See bMertansine [CPD:C20259]
Target
NCAM1 (CD56) [HSA:4684] [KO:K06491]
TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  Pathway
hsa04514  Cell adhesion molecules
hsa04540  Gap junction
Brite
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Cell adhesion molecules: Ig superfamiy
   CAMs
    NCAM1 (CD56)
     D09927  Lorvotuzumab mertansine (USAN/INN)
 Not elsewhere classified
  Cellular process
   Cytoskeleton
    TUBB
     D09927  Lorvotuzumab mertansine (USAN/INN)
Other DBs
CAS: 1008106-64-6
PubChem: 124490621
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system